Momenta Pharmaceuticals to Webcast Presentation at the 2019 Bank of America Merrill Lynch Healthcare Conference
May 09, 2019 08:00 ET
|
Momenta Pharmaceuticals, Inc.
CAMBRIDGE, Mass., May 09, 2019 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA), a biotechnology company focused on discovering and developing novel biologic therapeutics to treat...
Momenta Pharmaceuticals Reports First Quarter 2019 Financial and Operating Results
May 02, 2019 07:00 ET
|
Momenta Pharmaceuticals, Inc.
— M281 Phase 2 trials in MG and HDFN active and enrolling patients — — Data supporting M281’s mechanism in HDFN, as first anti-FcRn antibody to inhibit maternal-fetal IgG transfer in perfusion model...
Momenta Pharmaceuticals Announces Date of First Quarter 2019 Financial Results Conference Call and Webcast
April 18, 2019 08:00 ET
|
Momenta Pharmaceuticals, Inc.
CAMBRIDGE, Mass., April 18, 2019 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA), a biotechnology company focused on discovering and developing novel biologic therapeutics to treat...
Momenta Pharmaceuticals Announces Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2019
March 28, 2019 07:00 ET
|
Momenta Pharmaceuticals, Inc.
CAMBRIDGE, Mass., March 28, 2019 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA), a biotechnology company focused on discovering and developing novel biologic therapeutics to treat...
Momenta Pharmaceuticals Announces Publication of New Data Supporting M281 as First Anti-FcRn Antibody to Inhibit Maternal-Fetal IgG Transfer in the Human Term Placenta
March 21, 2019 08:43 ET
|
Momenta Pharmaceuticals, Inc.
Data supports M281’s potential to prevent placental transfer of disease-inducing antibodies from mother to fetus in alloimmune and autoimmune diseases of the fetus and newborn Global multi-center...
Momenta Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results
February 22, 2019 06:30 ET
|
Momenta Pharmaceuticals, Inc.
-- Ended 2018 with a cash position of $449.0 million -- -- Phase 2 trials of M281 in myasthenia gravis (MG) and hemolytic disease of the fetus and newborn (HDFN) underway; First healthy volunteer...
Momenta Pharmaceuticals Announces Date of Fourth Quarter and Year End 2018 Financial Results Conference Call and Webcast
February 08, 2019 08:00 ET
|
Momenta Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Feb. 08, 2019 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA), a biotechnology company focused on discovering and developing novel biologic therapeutics to treat...
Momenta Pharmaceuticals Announces Oral Presentation of New Data for M281 at the Society for Maternal-Fetal Medicine 2019 Annual Meeting
February 07, 2019 08:00 ET
|
Momenta Pharmaceuticals, Inc.
Study highlights ability of M281 to inhibit transfer of immunoglobulin G from maternal to fetal circulation in ex vivo placental perfusion modelM281 currently being evaluated in an international Phase...
Momenta Pharmaceuticals Announces First Subject Dosed in Phase 1/2 Clinical Trial of M254, Hypersialylated Immunoglobulin G
January 29, 2019 08:00 ET
|
Momenta Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Jan. 29, 2019 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA), a biotechnology company focused on discovering and developing novel biologic therapeutics to treat...
Momenta Pharmaceuticals to Webcast Presentation at the 37th Annual J.P. Morgan Healthcare Conference
January 02, 2019 08:00 ET
|
Momenta Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Jan. 02, 2019 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA), today announced that Craig Wheeler, President and CEO, will present at the 37th Annual J.P. Morgan...